

## Anti-alpha 5 beta 1 Integrin (Volociximab), Human IgG4 Antibody

<b>CATALOG NO:</b>	A1092-200
<b>ALTERNATIVE NAMES:</b>	Fibronectin receptor; CD49 antigen-like family member E; Integrin alpha-F; VLA-5; CD49e
<b>AMOUNT:</b>	200 µg
<b>IMMUNOGEN:</b>	Heterodimeric α5β1Fc fusion protein
<b>ISOTYPE / FORMAT:</b>	Human IgG4, kappa
<b>CLONALITY:</b>	Monoclonal
<b>CLONE:</b>	M200
<b>SPECIES REACTIVITY:</b>	Human
<b>FORM:</b>	Liquid
<b>SPECIFICITY:</b>	The antibody binds to human α5β1 integrin with a Kd of 0.367 nM (determined by Biacore), an EC50 of 0.2 nM and an IC50 of 2.3 nM.
<b>PURIFICATION:</b>	Affinity purified using Protein A
<b>FORMULATION:</b>	Supplied in PBS with preservative (0.02% Proclin 300)
<b>STORAGE CONDITIONS:</b>	Store at 4°C for upto 3 months. For long term storage, aliquot and freeze at -20°C. Avoid repeated freeze/thaw cycles.
<b>DESCRIPTION:</b>	Recombinant monoclonal antibody to alpha 5 beta 1 Integrin. Manufactured using recombinant technology with variable regions (i.e. specificity) from the hybridoma M200 (Volociximab). The antibody binds specifically to α5β1 integrin, which is part of the superfamily of glycoprotein transmembrane receptors for ligands such as fibronectin, vitronectin, laminins and collagens. The α5β1 integrin receptor plays a key role in cellular processes such as inflammation, cell proliferation, angiogenesis and tumour metastasis. Comprising the variable domain of the original mouse antibody, a chimeric mouse:human IgG4 version of this antibody has been tested in vivo: In cynomolgus monkeys with laser-induced choroidal neovascularization (CNV), in rabbit models and in human volunteers. The antibody reached Phase II clinical trials with PDL Biopharma and Biogen-Idec.
<b>APPLICATION:</b>	ELISA; FC; IF; Block; IHC
<b>REFERENCE:</b>	Ramakrishnan <i>et al.</i> Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5 (4):273-86

### RELATED PRODUCTS:

- Anti-VEGF (Bevacizumab), humanized Antibody (**Cat. No. A1045-100**)
- Anti-HER2 (Trastuzumab), humanized Antibody (**Cat. No. A1046-100**)
- Anti-EGFR (Cetuximab), Chimeric Antibody (**Cat. No. A1047-100**)
- Anti-TNF-α (Adalimumab), humanized Antibody (**Cat. No. A1048-100**)
- Anti-CD20 (Rituximab), Chimeric Antibody (**Cat. No. A1049-100**)
- Anti-EGFR (Panitumumab), humanized antibody (**Cat. No. A1050-100**)
- Anti-OX40L (Oxelumab), Human IgG1 Antibody (**Cat. No. A1088-200**)
- Anti-CD11a (Efalizumab), Human IgG1 Antibody (**Cat. No. A1089-200**)
- Anti-EGFR (Matuzumab), Human IgG1 Antibody (**Cat. No. A1090-200**)
- Anti-CD4 (Clenoliximab), Human IgG4 Antibody (**Cat. No. A1091-200**)
- Anti-TNF alpha (Humicade), Human IgG4 Antibody (**Cat. No. A1093-200**)
- Anti-CD40L (Ruplizumab), Human IgG1 Antibody (**Cat. No. A1094-200**)
- Anti-Human Ephrin Type A receptor 2 (1C1), Human IgG1 Antibody (**Cat. No. A1095-200**)
- Anti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Antibody (**Cat. No. A1096-200**)
- Anti-TNF alpha (Infliximab), Human IgG1 Antibody (**Cat. No. A1097-200**)
- Anti-IL-2R alpha (CD25) (Basiliximab), Human IgG1 Antibody (**Cat. No. A1098-200**)
- Anti-IL-2R alpha (Daclizumab), Human IgG1 Antibody (**Cat. No. A1099-200**)

**FOR RESEARCH USE ONLY! Not to be used on humans.**